Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

This trial is studying whether giving immunotherapy before surgery (called neoadjuvant therapy) helps people with early-stage lung cancer that carries rare genetic mutations. The goal is to shrink the tumor before removal and potentially improve long-term outcomes. **You may be eligible if:** - You are 18 or older - You have been diagnosed with Stage IIB–IIIB non-small cell lung cancer (NSCLC) - Your tumor carries a rare genetic change such as a RET fusion, BRAF mutation, HER2 exon 20 insertion, or MET amplification - Your tumor has not been previously treated with any cancer drugs or radiation - You are healthy enough to undergo lung surgery **You may NOT be eligible if:** - You have Stage I or Stage IV lung cancer - Your tumor has common EGFR or ALK mutations (these have different standard treatments) - You have small cell lung cancer - You have had active bleeding in the past 6 months - You are pregnant Talk to your doctor to see if this trial is right for you.